Ozmosi | betaine Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

betaine

Alternative Names: betaine
Clinical Status: Inactive
Latest Update: 2026-05-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Unknown

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Malaysia | Morocco | New Zealand | Norway | Pakistan | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: None

Company: China Rehabilitation Research Center, Beijing Boai Hospital
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for betaine

Countries in Clinic: China

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Hyperhomocysteinemia|Vitamin B Deficiency

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20250419

CTR20250419

P3

Completed

Hyperhomocysteinemia|Vitamin B Deficiency

2025-10-20

2025-12-14

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

CTR20253844

CTR20253844

P3

Active, not recruiting

Hyperhomocysteinemia

None

2026-05-30